Test Price
2,800 AED✅ Home Collection Available
PDE4D Gene Acrodysostosis Type 2 (ACRDYS2) Genetic Test in UAE | 2800 AED | DHA Licensed Lab
Executive Summary & Core Metrics
Executive Summary: Our ISO 15189 & ISO 9001:2015 certified genetic test delivers 99.9% diagnostic sensitivity for PDE4D gene mutations linked to Acrodysostosis Type 2. This next-generation sequencing (NGS) assay analyzes the full coding region of PDE4D using whole blood, extracted DNA, or FTA card samples. Turnaround time is 3–4 weeks. The service includes DHA-licensed specialist interpretation and VIP mobile phlebotomy home collection (8 AM – 11 PM daily). Corporate oversight: DNA Labs UAE, DHA Facility License 1143, Dubai Healthcare City.
Test Overview & Methodology
The PDE4D gene Acrodysostosis Type 2 (ACRDYS2) NGS test identifies pathogenic variants causing this rare skeletal dysplasia, characterized by short stature, brachydactyly, nasal hypoplasia, and multi-hormone resistance. Prior to testing, a mandatory genetic counselling session to draw a pedigree chart and collect clinical history is conducted. Our test, performed under UAE regulatory standards, empowers precise diagnosis and timely intervention for pediatric and adult patients.
| Feature | Our Test (DNA Labs UAE) | Standard Lab (UAE) |
|---|---|---|
| Technology | NGS – full coding region coverage | PCR + Sanger (limited target) |
| Turnaround Time | 3–4 Weeks | 4–8 Weeks |
| Specimen Types | Whole Blood, Extracted DNA, FTA Card (One drop) | Whole Blood only |
| Home Collection | Included (8 AM–11 PM) | Not available |
Physician Insight & Safety Protocols
"As a DHA-licensed Consultant Medical Genetics, I emphasize that PDE4D genetic test results must be correlated with clinical and radiological findings for a definitive diagnosis of Acrodysostosis Type 2; a negative result does not exclude other skeletal dysplasias. Families should understand that this test is a crucial step in personalized management, but clinical judgment remains paramount." — Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Pre-Test Advisory
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. This test does not replace ongoing endocrine or orthopedic management. Sudden cessation of hormone therapy or other drugs may lead to serious health risks.
Exclusion Criteria & Emergency Red Flags
- Active febrile illness or acute infection at time of draw (reschedule).
- Severe anemia (Hb <8 g/dL) or bleeding disorders; medical clearance required.
- If patient experiences sudden onset of respiratory distress, seizures, or severe bone pain after sample collection, seek immediate emergency care.
- History of severe epistaxis or bruising tendency – inform phlebotomist before venipuncture.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the PDE4D Genetic Test?
This test identifies pathogenic variants in the PDE4D gene to confirm Acrodysostosis Type 2, guiding endocrinology and orthopedics follow-up. It provides clarity for families with a child exhibiting short stature and brachydactyly, enabling targeted surveillance for hormone resistance and early developmental support.
2. How is the sample collected and is home service available?
A DHA-licensed phlebotomist collects your sample at home from 8 AM to 11 PM using certified cold-chain transport. The blood or FTA card sample is then securely transported to our ISO-certified NGS laboratory, ensuring integrity throughout the process.
3. What do the results mean and how will I receive them?
Your report clearly interprets any PDE4D mutation and its significance, with negative result indicating other causes. Results are delivered via a secure patient portal and discussed in a telephonic post-guidance session with a clinical geneticist who will explain next steps and referrals.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This service fully adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All sample handling meets ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and DHA facility license 1143. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Corporate operator: DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | PDE4D Gene Acrodysostosis Type 2 (ACRDYS2) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | Q77.4 (Acrodysostosis) |
| LOINC Code | 87833-5 (Gene mutations identified in Specimen by Sequencing) |
| DHA Facility License & Laboratory Address | DHA License 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians